Meisoindigo for the treatment of chronic myelogenous leukaemia [1]

British Journal of Haematology

Volumn 111, Issue 2, 2000, Pages 711-712

  Casaña, Pilar ^a,b   Martínez, Francisco ^b   Haya, Saturnino ^a   Lorenzo, Ignacio ^a   Espinós, Carmen ^a   Aznar, José A ^a  

^a Unidad de Coagulopatías Congénitas de la Comunidad Valenciana   (Spain)

^b HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

Chronic myelogenous leukaemia; Meisoindigo; Treatment

Indexed keywords

CHINESE DRUG; MEISOINDIGO; UNCLASSIFIED DRUG;

CHINESE MEDICINE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; HUMAN; LETTER; LEUKEMIA CELL; PRIORITY JOURNAL; TRADITIONAL MEDICINE; TREATMENT OUTCOME;

DRUG THERAPY, COMBINATION; DRUGS, CHINESE HERBAL; HUMANS; HYDROXYUREA; INDOLES; LEUKEMIA, MYELOID, CHRONIC; NUCLEIC ACID SYNTHESIS INHIBITORS; RANDOMIZED CONTROLLED TRIALS; RETROSPECTIVE STUDIES;

EID: 0034536046     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2000.02357.x     Document Type: Letter

References (5)

1. Phase III clinical trial on meisoindogo in the treatment of chronic myelogenous leukaemia
2. Clinical studies of 134 cases of CML treated with meisoindigo
3. Indirubin, the active constituent of a chinese antileukemia medicine, inhibits cycle-dependent kinase
4. Studies on antineoplastic action of N-methlisoindirubin
5. Sequential homoharringtonine and interferon-α in the treatment of early chronic phase chronic myelogenous leukemia